SciSparc Announces MitoCareX Unveils Groundbreaking Discovery Of Small Molecule Structure In Anti-Cancer Research
SciSparc Announces MitoCareX Unveils Groundbreaking Discovery Of Small Molecule Structure In Anti-Cancer Research
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently
MitoCarex Bio致力於創建預測性人工智能模型，以更有效地預測小分子
TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company's venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, had virtually screened millions of small molecules by using its computationally advanced drug discovery platform, which resulted in the identification of several molecules that could be used for potential anti-cancer treatments.
以色列特拉維夫，2024年3月21日（環球新聞專線）——專注於開發治療中樞神經系統疾病療法的專業臨床階段製藥公司ScisPARC Ltd.（納斯達克股票代碼：SPRC）（“公司” 或 “ScisPARC”）宣佈，該公司與阿隆·西爾伯曼博士合資的專注於藥物領域的MitoCarex Bio Ltd.（“MitoCarex”）（“MitoCarex”）通過靶向線粒體 SLC25 蛋白家族的癌症療法的發現和開發，已經使用其計算先進的藥物虛擬篩選了數百萬個小分子發現平台，該平台確定了幾種可用於潛在抗癌治療的分子。
As previously announced by the Company on March 12, 2024, by using its in-vitro screening systems related to the mitochondria, MitoCareX corroborated its virtual findings by confirming the anti-cancer biological activity of several small molecule structures.
正如該公司先前在2024年3月12日宣佈的那樣，通過使用與線粒體相關的體外篩選系統，MitoCarex確認了幾種小分子結構的抗癌生物活性，從而證實了其虛擬發現。
Additionally, by utilizing the extensive virtual data generated, MitoCareX is working towards creating a predictive AI model. This model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target its SLC25 protein of interest.
此外，通過利用生成的大量虛擬數據，MitoCarex正在努力創建預測性人工智能模型。該模型有望使MitoCarex能夠更有效地在更廣泛的化學空間中航行，目標是發現更多靶向其感興趣的 SLC25 蛋白的新型抗癌支架。
譯文內容由第三人軟體翻譯。